Italy / Market Access Reform: A Watershed Moment?
In recent months, a profound transformation has been occurring right at the core of the Italian pharmaceutical…
Sanofi Italy
Last updated: 19.04.2016
Sanofi, a leader in global health, discovers, develops and distributes therapeutic solutions, focused on the needs of patients.
Sanofi has a strong presence in Italy with offices in Milan, a Genzyme headquarters in Modena, industrial plants from north to south of the country and over 2,500 employees.
Sanofi Italy produces and markets drugs in all areas of activity of the Group, including: cardiovascular, diabetes, oncology, hematology, rare diseases and multiple sclerosis with Sanofi Genzyme, generics with Zentiva, and animal health with Merial.
In Italy, there is also a unit dedicated to the clinical trials on new drugs and a center of biotechnology at the Brindisi plant which carries out research on antibiotics.
Contact
Related
Italy / Mandatory COVID-19 Vaccines for Healthcare Workers; Chiesi & Angelini’s AI Investments; Sputnik V Manufacturing
The latest Italy Pharma News, including the government’s decision to make COVID-19 vaccines mandatory for all…
Italy / Stevanato’s $5 bn valuation; Zolgensma Approval; Sputnik V Manufacturing
The latest from Italian pharma, including the foreign minister’s plea for delivering on COVID-19 vaccine…
Italy / Menarini CEO on Averting Future Health Crises; Alfasigma Hackathon; January COVID Vaccines
A roundup of some of the most important recent stories from Italian pharma, including an in-depth interview with…
Pricing / Italy Takes Global Transparency Lead by Forcing Pharma to Disclose Public R&D Funding
In July 2020, Italy became the first country in the world to mandate pharma companies to disclose data surrounding…
News Roundup / Italy Pharma July 2020
Below we present recent news from Italy’s biopharma industry, including the recent acquisition of Stemline…
M&A / Menarini Makes Big US Oncology Move with Stemline Acquisition
Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US…
Internationalization / Chiesi Moves into Rare Diseases & the US Market
Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based…
Interview: Luca G. Guidotti – Deputy Scientific Director, San Raffaele…
Prof. Luca G. Guidotti discusses the esteemed positioning of San Raffaele within the global scientific community,…
Interview: Gianvito Martino – Scientific Director & Director of the…
The division of neuroscience at the San Raffaele Scientific Institute is one of the best worldwide performers in…
Interview: Angelo Corti – Director, Division of Experimental Oncology, San…
Professor Angelo Corti, Director of the Experimental Oncology division of the SRSI, discusses approaches to…
Interview: Paola Pozzi – Head, Office of Biotechnology Transfer, San…
Dr. Paola Pozzi, the head of the Office of Biotechnology Transfer at the San Raffaele Scientific Institute,…
